The thesis

ONC is a biotechnology company with a 29.6% YoY revenue growth and 8782.0% gross margin. The conviction score is 32/100, indicating medium conviction. Analyst consensus is BUY. The high valuation at 84.8x P/E is a concern.

Why now

The upcoming Trump-Xi summit may impact the biotech sector, and ONC's revenue growth is a key indicator to watch. The current tightening monetary policy environment is driving expectations of curtailing consumer discretionary spending.

What to watch

ONC's next quarter revenue growth and any updates on its commercial stage products, such as BRUKINSA, will be key indicators. The impact of the Trump-Xi summit on the biotech sector will also be important to watch.

Key risks

The high valuation of 84.8x P/E poses a valuation risk. Execution risk is also present given the company's high net margin of 1068.0% and the need to sustain revenue growth. Macro risk from tightening monetary policy is another concern.

Theme exposure